Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Trial Profile

Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Luminespib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 27 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top